Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

ADMA Biologics Inc (NDAQ:ADMA) Upgraded by Raymond James to “Mkt Perform” from “Mkt Perform” Rating

Raymond James ADMA Biologics Inc NDAQ:ADMA

ADMA Biologics Inc (NDAQ:ADMA) Upgrade of Rating

Adma Biologics Inc (NDAQ:ADMA) was upped by research analysts at Raymond James from “Mkt Perform” rating to “Outperform” rating in an analyst note issued on Tuesday morning.

ADMA Stock Chart

Institutional Ownership

Aisling Capital Llc had the largest stake with ownership of 3.61M shares as of Q2 2015 for 5.39% of the stocks portfolio. Consonance Capital Management Lp is another bullish investment professional who is possessing 1.27M shares of ADMA Biologics Inc or 0.89% of their stocks portfolio. Further, Broadfin Capital Llc have 0.72% of their stocks portfolio invested in the company for 1.11M shares. The New York-based fund Iguana Healthcare Management Llc revealed it had purchased so far a stake worth about 0.39% of the investment professional’s Stock portfolio in ADMA Biologics Inc. The New York-based fund Perceptive Advisors Llc is also positive about the stock, possessing 150,000 shares or 0.34% of their stocks portfolio.

ADMA Biologics Inc (NDAQ:ADMA) Profile

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate.

ADMA Biologics Inc (NDAQ:ADMA) traded up 10.89% on 14 November, hitting $2.75. A total of 580,421 shares of the company’s stock traded hands. This is up from average of 118,533 shares. ADMA Biologics Inc has a 52 week low of $2.01 and a 52 week high of $6.88. The company has a market cap of $70.93 million and a P/E ratio of 0.

Get the latest ADMA Biologics Inc (NDAQ:ADMA) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post ADMA Biologics Inc (NDAQ:ADMA) Upgraded by Raymond James to “Mkt Perform” from “Mkt Perform” Rating appeared first on Octafinance.

This post first appeared on Octafinance – Financial News, Reports And Intell, please read the originial post: here

Share the post

ADMA Biologics Inc (NDAQ:ADMA) Upgraded by Raymond James to “Mkt Perform” from “Mkt Perform” Rating


Subscribe to Octafinance – Financial News, Reports And Intell

Get updates delivered right to your inbox!

Thank you for your subscription